0.00Open0.00Pre Close0 Volume0 Open Interest1.50Strike Price0.00Turnover423.46%IV-127.27%PremiumDec 20, 2024Expiry Date0.84Intrinsic Value100Multiplier5DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9155Delta0.4700Gamma0.78Leverage Ratio-0.0044Theta-0.0002Rho-0.71Eff Leverage0.0001Vega
BriaCell Therapeutics Stock Discussion
$Checkpoint Therapeutics (CKPT.US)$ $Fortress Biotech (FBIO.US)$ FDA approval of drug for metastatic cutaneous squamous cell carcinoma. This drug is the first and only progr...
Benzinga· 1 min ago
BriaCell 2024 SABCS® Poster Highlights Ability of Bria-IMT™ Regimen to Increase Cancer-Fighting Immune Cells in Metastatic Breast Cancer
Friday, 13th December at 7:50 am
BriaCell reports influx of cancer fighting CD8+ "killer" T cell into metastatic breast cancer tumors and lymph organs turning "Cold" tumors and lymph nodes "Hot" on ImmunoPET imaging in cancer patients treated with Bria-IMT™ plus an immune checkpoint inhibitor (CPI)
Imaging confirms clinical...
Briacell Therapeutics Announces Proposed Public Offering
BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCS®
Wednesday, 11th December at 7:50 am
Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months for those treated since 2022), double that of comparable patients in the literature
Final Phase 2 OS calculation is pending as many patients remain alive well over 1 year after starting...
No comment yet